Biogen (BIIB) Tops Q3 EPS by 93c; updates guidance

Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.81, $0.93 better than the analyst estimate of $3.88. Revenue for the quarter came in at $2.53 billion versus the consensus estimate of $2.34 billion.

GUIDANCE:

Biogen sees FY2025 EPS of $14.50-$15.00, versus the consensus of $15.76.

Increased expected full year 2025 total revenue to be approximately flat to increasing 1%, at constant currency, versus full year 2024, up from approximately flat previously

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• FOMC minutes from July 28-29th meeting
• Legence Corp (LGN) PT Raised to $130 at Tigress Financial Partners
• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance